Eli Lilly and Company has taken the lead in in the development and tirzepatide, a groundbreaking treatment for type 2 diabetes. Tirzepatide, a dual GIP and GLP-1 receptor agonist, demonstrates significant capacity to improve glycemic control and reduce cardiovascular risks. The complex manufacturing process of tirzepatide requires a series of caref